Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Mar 2023
According to market research firm Euromonitor, the global children's cough, cold and allergy products market in 2022 is worth $2.5 billion.
Read Full NewsA trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.
Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.
Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.
Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.
The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.
1.
Woman Loses 6-Year Battle With Mouth Tumor
2.
Skipping Lymph Node Biopsy Gains Ground in Breast Cancer
3.
Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.
4.
EMA OKs Two Treatments for Small Cell Lung Cancer
5.
Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma
1.
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification
2.
Acrochordon: What It Is, Causes, And How To Manage This Skin Condition
3.
Unlocking the Mysteries of ICD 10 Code Normocytic Anemia
4.
The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v
5.
Cold Antibody AIHA and Neoplastic Disorders: Unraveling the Clinical and Pathogenic Link
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge